TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22633322

Group type: EXPERIMENTAL
Intervention: Na-ASP-2 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hepatitis B vaccine
Number of subjects: 0
Study: 22633346

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial transfer (DMET) for Fuchs endothelial dystrophy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial transfer (DMET) for bullous keratopathy
Number of subjects: 12
Study: 22633629

Group type: EXPERIMENTAL
Intervention: Adjunctive topiramate
Number of subjects: 284
Study: 22633670

Group type: EXPERIMENTAL
Intervention: Baseline plasma cardiac troponin I levels
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Age and disease onset
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Echocardiogram parameters
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Baseline electrocardiograms
Number of subjects: 49
Study: 22634397

Group type: EXPERIMENTAL
Intervention: Iniparib plus paclitaxel and carboplatin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study: 22634437

Group type: EXPERIMENTAL
Intervention: EV71 vaccine 160U (only for children)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EV71 vaccine 320U
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EV71 vaccine 640U
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EV71 vaccine (all doses)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EV71 vaccine (one dose)
Number of subjects: 100
Study: 22634621

Group type: EXPERIMENTAL
Intervention: AAT-treated stimulated DC (0.5 mg/ml human AAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAT treatment (60 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAT-treated cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAT-treated DC
Number of subjects: 0
Study: 22638007

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT) for depression
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 135
Study: 22639293

Group type: EXPERIMENTAL
Intervention: Lipid infusion (20% Intralipid at 90 ml/h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Glycerol infusion (2.25 g/100 ml at 90 ml/h)
Number of subjects: 28
Study: 22639402

Group type: EXPERIMENTAL
Intervention: Dissociative subtype of PTSD (high PTSD severity with high levels of dissociation)
Number of subjects: 644
Study: 22640652

Group type: EXPERIMENTAL
Intervention: Seasonal flu vaccine (SFV) - 1 dose, Mutagrip®
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: A/H1N1 flu vaccine (HFV) - 2 doses at a 3-week interval, Panenza®
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Both vaccines (SFV and HFV)
Number of subjects: 199
Study: 22642956

Group type: EXPERIMENTAL
Intervention: Single-channel mucosal impedance (MI) catheter measurements at the site of erosive mucosa
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Single-channel mucosal impedance (MI) catheter measurements at 2 cm above the squamocolumnar junction in patients with GERD
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Single-channel mucosal impedance (MI) catheter measurements along the esophagus in patients with GERD
Number of subjects: 69
Study: 22643560

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 3 weeks) and Erlotinib (150 mg daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bevacizumab and Erlotinib
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (historical control from Sorafenib trial)
Number of subjects: 21
Study: 22644887

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) and near-infrared spectroscopy (NIRS) monitoring during liver transplantation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) and near-infrared spectroscopy (NIRS) monitoring
Number of subjects: 9
Study: 22644957

Group type: EXPERIMENTAL
Intervention: Endocytoscopy (EC) with methylene blue or toluidine blue application
Number of subjects: 40
Study: 22645182

Group type: EXPERIMENTAL
Intervention: Dasatinib (first-line therapy)
Number of subjects: 0
Study: 22646832

Group type: EXPERIMENTAL
Intervention: Ipsilateral leg (Villalta score)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Contralateral leg (Villalta score)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Ipsilateral PTS (defined by Villalta score >4)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Contralateral leg (Villalta score >4)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Correlation of Villalta scores
Number of subjects: 367
Study: 22647431

Group type: EXPERIMENTAL
Intervention: Etanercept therapy (anti-TNF) for 12 weeks
Number of subjects: 97
Study: 22647519

Group type: EXPERIMENTAL
Intervention: Continuous IV infusion of adenosine via the forearm vein (140 μg/min/kg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Continuous IV infusion of adenosine via the femoral vein (140 μg/min/kg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intracoronary bolus injection of adenosine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Additional bolus injection of adenosine during IV infusion
Number of subjects: 71

Group type: COMPARATOR
Intervention: Both routes of adenosine infusion (femoral vs. forearm)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Hyperemic mean transit time and index of microcirculatory resistance
Number of subjects: 71
Study: 22647561

Group type: EXPERIMENTAL
Intervention: VolumeView/EV1000™ system
Number of subjects: 72

Group type: COMPARATOR
Intervention: PiCCO™ method
Number of subjects: 72
Study: 22648179

Group type: EXPERIMENTAL
Intervention: Weekly dosing of trastuzumab emtansine (T-DM1) at 2.4 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Weekly dosing of trastuzumab emtansine (T-DM1)
Number of subjects: 28
Study: 22648486

Group type: EXPERIMENTAL
Intervention: Serial limited compression ultrasonography (CUS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single complete compression ultrasonography (CUS)
Number of subjects: 0
Study: 22649106

Group type: EXPERIMENTAL
Intervention: GATA2 zinc finger 1 mutations in biCEBPA-positive CN-AML patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: GATA2 mutations presence
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GATA2 mutations (n=10)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GATA2 ZF1 mutants in reporter gene assays
Number of subjects: 33
Study: 22649108

Group type: EXPERIMENTAL
Intervention: Multidimensional flow cytometry (MDF) for detecting residual disease (RD)
Number of subjects: 249
Study: 22649177

Group type: EXPERIMENTAL
Intervention: Focused sonographic examination of the heart, lungs and deep veins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual diagnostic work up
Number of subjects: 0
Study: 22651703

Group type: EXPERIMENTAL
Intervention: Vemurafenib alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vemurafenib and GDC-0973 combination
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vemurafenib in mice with drug-resistant A375 xenografts
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vemurafenib and GDC-0973 combination efficacy
Number of subjects: 20
Study: 22651868

Group type: EXPERIMENTAL
Intervention: LNA-34a (locked nucleic acid modified inhibitor)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Overexpression of miR-34a
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pre-treatment of BMCs with LNA-34a ex vivo
Number of subjects: 49

Group type: COMPARATOR
Intervention: BMCs from patients with myocardial infarction
Number of subjects: 49
Study: 22652031

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 77

Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 77
Study: 22652104

Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal external beam accelerated partial breast irradiation (3D-APBI) at 32 Gy delivered in 8 twice-daily fractions
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 3D-APBI
Number of subjects: 98
Study: 22653976

Group type: EXPERIMENTAL
Intervention: Bortezomib combined with vincristine, dexamethasone, pegylated asparaginase, and doxorubicin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bortezomib combined with chemotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bortezomib combined with chemotherapy and prophylactic antibiotics (vancomycin, levofloxacin, voriconazole)
Number of subjects: 22
Study: 22655593

Group type: EXPERIMENTAL
Intervention: Encapsulated cell biodelivery (ECB) implants delivering nerve growth factor (NGF)
Number of subjects: 6
Study: 22656234

Group type: EXPERIMENTAL
Intervention: Rituximab (750 mg/m(2) on days 1, 8, 15, and 22) and Temozolomide (150 mg/m(2) days 1-7 and 15-21) followed by consolidation Temozolomide (150-200 mg/m(2) × 5/28 days) and maintenance with Methylprednisolone (1 g IV every 28 days) until progression
Number of subjects: 16
Study: 22658128

Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 antibody (0.3 to 10 mg/kg, administered every 14 days in 6-week cycles for up to 16 cycles)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 antibody
Number of subjects: 207
Study: 22658254

Group type: EXPERIMENTAL
Intervention: Early abciximab administration before primary PCI
Number of subjects: 262

Group type: COMPARATOR
Intervention: Late abciximab administration before primary PCI
Number of subjects: 262
Study: 22659939

Group type: EXPERIMENTAL
Intervention: VO2peak >27.3 ml/kg/min
Number of subjects: 51

Group type: COMPARATOR
Intervention: VO2peak ≤27.3 ml/kg/min
Number of subjects: 51
Study: 22659961

Group type: EXPERIMENTAL
Intervention: Wood-smoke exposure (WSE)
Number of subjects: 914

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 914
Study: 22660962

Group type: EXPERIMENTAL
Intervention: Compression ultrasound of a forearm vein (CUS)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Inferior vena cava collapsibility (IVC-C)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Internal jugular vein collapsibility (IJV-C)
Number of subjects: 81
Study: 22661451

Group type: EXPERIMENTAL
Intervention: PCWP 16 to 18 mm Hg
Number of subjects: 268

Group type: COMPARATOR
Intervention: PCWP ≤ 15 mm Hg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: PCWP increased to 19 mm Hg
Number of subjects: 268

Group type: COMPARATOR
Intervention: PCWP ≤ 18 mm Hg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: All PCWP subgroups
Number of subjects: 268
Study: 22661464

Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis
Number of subjects: 21
Study: 22661474

Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly intravitreal injections)
Number of subjects: 0
Study: 22661483

Group type: EXPERIMENTAL
Intervention: Inner zone atrophy
Number of subjects: 413

Group type: COMPARATOR
Intervention: Outer zone atrophy
Number of subjects: 413

Group type: COMPARATOR
Intervention: Superior outer subfield atrophy
Number of subjects: 413
Study: 22661748

Group type: EXPERIMENTAL
Intervention: Impaired autoregulation during CPB (Mx ≥0.40)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Impaired autoregulation (Mx ≥0.40)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Preserved autoregulation (Mx <0.40)
Number of subjects: 234
Study: 22662137

Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies against EV71 in infants at 2 months
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Maternal antibody titers
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Accumulate incidence density of HFMD
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Seropositivity of EV71 antibody in infants
Number of subjects: 975
Study: 22664059

Group type: EXPERIMENTAL
Intervention: Flavopiridol (100 mg/m2 IV, 24 h infusion) and Cisplatin (60 mg/m2 IV)
Number of subjects: 45
Study: 22664410

Group type: EXPERIMENTAL
Intervention: Taking Action Together (TAT) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22665938

Group type: EXPERIMENTAL
Intervention: CRd (carfilzomib 36 mg/m2, lenalidomide 25 mg/d, dexamethasone 40/20 mg)
Number of subjects: 53
Study: 22666789

Group type: EXPERIMENTAL
Intervention: Case arm (urolithiasis)
Number of subjects: 51
Study: 22668067

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg (single dose on day 1 and once daily on days 3-7)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg (single dose and once-daily doses for 5 days)
Number of subjects: 16
Study: 22670903

Group type: EXPERIMENTAL
Intervention: Vismodegib (150 mg oral daily)
Number of subjects: 96
Study: 22673018

Group type: EXPERIMENTAL
Intervention: Light activity
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MVPA accumulated in bouts
Number of subjects: 102

Group type: COMPARATOR
Intervention: Activity variables
Number of subjects: 102
Study: 22674435

Group type: EXPERIMENTAL
Intervention: L19-TNF ILP at 325 µg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L19-TNF ILP at 650 µg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard melphalan-containing ILP
Number of subjects: 17
Study: 22676070

Group type: EXPERIMENTAL
Intervention: Risperidone (2 to 6 mg/day) for 6 months
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Risperidone (2 to 6 mg/day) for 12 months
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Risperidone (2 to 6 mg/day)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Risperidone maintenance treatment
Number of subjects: 390
Study: 22676992

Group type: EXPERIMENTAL
Intervention: Intrauterine fetal death (IUFD)
Number of subjects: 368
Study: 22677155

Group type: EXPERIMENTAL
Intervention: Lenalidomide (20 mg) plus rituximab
Number of subjects: 52
Study: 22677240

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) in the Geriatric Department (GD)
Number of subjects: 3877

Group type: COMPARATOR
Intervention: General medical care in the Medical Department (MD)
Number of subjects: 3877
Study: 22677278

Group type: EXPERIMENTAL
Intervention: Beat Averaging (BA) using one beat
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Beat Averaging (BA) using two beats
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Beat Averaging (BA) using three beats
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Variable type (slopes and calculated variables)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Variable type (chamber dimensions, areas, velocities, and time intervals)
Number of subjects: 173
Study: 22677455

Group type: EXPERIMENTAL
Intervention: Concordant LV leads
Number of subjects: 103

Group type: COMPARATOR
Intervention: Discordant LV leads
Number of subjects: 103

Group type: COMPARATOR
Intervention: Discordant LV leads (+1 segment)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Discordant LV leads (+2 segments)
Number of subjects: 103
Study: 22681857

Group type: EXPERIMENTAL
Intervention: Health status measured using a visual analogue scale (VAS)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Waiting List Impact Questionnaire (WLIQ)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Independent predictors of lower VAS scores
Number of subjects: 150
Study: 22681919

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg dose)
Number of subjects: 59
Study: 22682017

Group type: EXPERIMENTAL
Intervention: IGF-1R monoclonal antibody therapy (R1507, IMC-A12, SCH 717454, CP-751.871)
Number of subjects: 12
Study: 22682069

Group type: EXPERIMENTAL
Intervention: Early surgical intervention (surgery within 6 months of birth)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late surgical intervention (surgery after 6 months of birth)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnosis obtained in utero
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diagnosis obtained at birth
Number of subjects: 0
Study: 22682146

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (Norditropin®)
Number of subjects: 120
Study: 22682691

Group type: EXPERIMENTAL
Intervention: Recurrent, personalized, paper-based educational messages and reminders sent via post.
Number of subjects: 0
Study: 22684655

Group type: COMPARATOR
Intervention: 3rd SUA tertile
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SUA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: serum creatinine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sTNF-alpha
Number of subjects: 100
Study: 22685032

Group type: EXPERIMENTAL
Intervention: TLR3-ligand polyinosinic: polycytidylic acid (poly(I:C))
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Colonic epithelial cell lines HT-29 and SW620
Number of subjects: 133

Group type: COMPARATOR
Intervention: Active IBD (UC and CD)
Number of subjects: 133
Study: 22685225

Group type: EXPERIMENTAL
Intervention: Secondary prevention treatment for children diagnosed with RHD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echocardiographic evaluation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiac auscultation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigation of risk factors associated with diagnosis and progression of RHD
Number of subjects: 0
Study: 22687305

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 81
Study: 22688151

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 100
Study: 22689675

Group type: EXPERIMENTAL
Intervention: Extramedullary disease presence
Number of subjects: 1965
Study: 22691114

Group type: EXPERIMENTAL
Intervention: AG+AA genotype of SNP c.-238G>A of TNFα gene
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Carriers positive for AG+AA genotype and A-allele of SNP c.-308G>A
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Genetic variants of TNFα
Number of subjects: 942
Study: 22691124

Group type: EXPERIMENTAL
Intervention: Bioactive glass (BioRestore™, Inion Oy, Tampere, Finland) used in socket ridge preservation procedure
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bioactive glass (BioRestore™, Inion Oy, Tampere, Finland)
Number of subjects: 13
Study: 22692507

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 559
Study: 22693172

Group type: EXPERIMENTAL
Intervention: Anti-Müllerian hormone (AMH) at a cut-off value of 20 pmol/l
Number of subjects: 262

Group type: COMPARATOR
Intervention: Morphologic description (PCOM)
Number of subjects: 262
Study: 22693229

Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella vaccination (MMR)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella revaccination (MMR) 4-5 years later
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Initial study vaccination with HIV load ≤400 copies/mL
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Grade 3 fever or fatigue
Number of subjects: 193
Study: 22693347

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 6166

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 6166
Study: 22694756

Group type: EXPERIMENTAL
Intervention: Exercise (n=22)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (n=15)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Neuro Emotional Technique (n=20)
Number of subjects: 57
Study: 22695105

Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D3 from fish oil capsules
Number of subjects: 55

Group type: COMPARATOR
Intervention: Multivitamin tablets
Number of subjects: 55
Study: 22695254

Group type: EXPERIMENTAL
Intervention: Ridaforolimus (50 mg intravenous once weekly)
Number of subjects: 38
Study: 22695763

Group type: EXPERIMENTAL
Intervention: EnSite™ NavX™ system during biventricular (BiV) pacing
Number of subjects: 5

Group type: COMPARATOR
Intervention: EnSite™ NavX™ system during right ventricle (RV) pacing
Number of subjects: 5

Group type: COMPARATOR
Intervention: M-mode echocardiography (echo) for reference
Number of subjects: 5
Study: 22695871

Group type: EXPERIMENTAL
Intervention: 4-5 cups coffee/day
Number of subjects: 489706

Group type: EXPERIMENTAL
Intervention: ≥6 cups coffee/day
Number of subjects: 489706

Group type: EXPERIMENTAL
Intervention: ≥6 cups coffee/day (proximal tumors)
Number of subjects: 489706

Group type: EXPERIMENTAL
Intervention: Predominantly decaffeinated coffee
Number of subjects: 489706

Group type: COMPARATOR
Intervention: Tea
Number of subjects: 489706
Study: 22696017

Group type: EXPERIMENTAL
Intervention: JE-VC (Ixiaro)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: JE-MB
Number of subjects: 120
Study: 22696176

Group type: EXPERIMENTAL
Intervention: 400 μg inhaled salbutamol
Number of subjects: 1831
Study: 22696435

Group type: EXPERIMENTAL
Intervention: Cholesteryl ester transfer protein-inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22698490

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 752
Study: 22698532

Group type: EXPERIMENTAL
Intervention: Aortic valve calcium (AVC) present (n = 894, 13.4%)
Number of subjects: 6685
Study: 22698649

Group type: EXPERIMENTAL
Intervention: Mass eradication of H pylori infection (1-week clarithromycin-based triple therapy followed by 10-day levofloxacin-based triple therapy for treatment failures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mass eradication of H pylori infection
Number of subjects: 0
Study: 22699291

Group type: EXPERIMENTAL
Intervention: South Asians (SAs)
Number of subjects: 6040
Study: 22699662

Group type: EXPERIMENTAL
Intervention: New technologies evaluated by the PEARL Network
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparative effectiveness research conducted by the PEARL Network
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinical studies participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benchmarking as a form of continuous feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaboration with oral health care and pharmaceutical industries
Number of subjects: 0
Study: 22699667

Group type: EXPERIMENTAL
Intervention: Oral cGVHD (defined by NIH scale >2 points)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression model including albumin, mouth pain, and total complement
Number of subjects: 187
Study: 22699693

Group type: EXPERIMENTAL
Intervention: Adapted physical activity program (123 sessions over one year)
Number of subjects: 0
Study: 22699956

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 85